13 Spinal Muscular Atrophy Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Tucson

NCT04088071Recruiting

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize rea...

Tucson, AZ20,000 participantsHeart Rhythm Clinical and Research Solutions, LLC

View Study Details

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Tucson, AZPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT06692738Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

Tucson, AZPHASE31,160 participantsAstraZeneca

View Study Details

NCT06077760Recruiting

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (...

Tucson, AZPHASE3868 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06095583Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination w...

Tucson, AZPHASE3756 participantsShanghai Junshi Bioscience Co., Ltd.

View Study Details

NCT06623422Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

Tucson, AZPHASE3680 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04613596Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and ...

Tucson, AZPHASE2626 participantsMirati Therapeutics Inc.

View Study Details

NCT06712355Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherap...

Tucson, AZPHASE3621 participantsBioNTech SE

View Study Details

NCT07063745Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

Tucson, AZPHASE2590 participantsBristol-Myers Squibb

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Tucson, AZPHASE3474 participantsNRG Oncology

View Study Details

NCT06616584Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

Tucson, AZPHASE2378 participantsSWOG Cancer Research Network

View Study Details

NCT07216209Recruiting

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-oper...

Tucson, AZNA48 participantsUniversity of Arizona

View Study Details

NCT06069570Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung ...

Tucson, AZPHASE148 participantsKiromic BioPharma Inc.

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Tucson

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 13 spinal muscular atrophy clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 27,459 participants. Research is being sponsored by Heart Rhythm Clinical and Research Solutions, LLC, National Cancer Institute (NCI), AstraZeneca and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Tucson — FAQ

Are there spinal muscular atrophy clinical trials in Tucson?

Yes, there are 13 spinal muscular atrophy clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 13 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated September 4, 2026 from ClinicalTrials.gov